Kanvas Biosciences, a spatial biology company, has unveiled clinical trial results at the 2024 Society for Immunotherapy of Cancer (SITC) meeting, showing the potential of fecal microbiota transplantation (FMT) in combination with anti-PD-1 re-induction to treat patients with microsatellite instability-high…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will present new data on a range of B-cell malignancies and treatments at the 66th ASH Annual Meeting in San Diego, December 7-10. The…
Moderna announced that Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older. “This approval demonstrates how our mRNA platform can tackle significant…
AstraZeneca will present new data from its cutting-edge hematology portfolio and pipeline at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from December 7 to 10, 2024. The company will showcase 57 abstracts, featuring 13 approved and…
The recently released Global Tuberculosis Report 2024 provides an updated overview of the challenges and progress in the global fight against tuberculosis (TB) during 2023. TB affected 10.8 million people in 2023, claiming approximately 1.25 million lives, including 161,000 deaths…
Sarepta Therapeutics a leader in precision genetic medicine for rare diseases, has announced its financial results for the third quarter of 2024, showcasing strong revenue growth and significant progress in its portfolio. “We’re pleased to report another strong quarter, with…
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported its financial results for the third quarter ending September 30, 2024. Teva’s President and CEO, Richard Francis, commented, “We’ve achieved our seventh consecutive quarter of growth, with global revenues reaching…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced the design of a pivotal Phase 3 clinical trial for ION582, an investigational treatment for Angelman syndrome (AS), following successful alignment with the U.S. Food and Drug Administration (FDA). AS is a rare…
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-driven cancers, reported its third-quarter financial results for the period ending September 30, 2024, and shared updates on corporate progress. The company’s mission centers on…
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company specializing in treatments for central nervous system (CNS) disorders, has announced positive results from Study 304, which evaluated the efficacy and safety of lumateperone 42 mg for preventing relapse in adults with…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced the appointment of Alan Bash as the President of CARVYKTI®. In this newly established position, Mr. Bash will oversee the ongoing growth of CARVYKTI®, managing Legend Biotech’s…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the launch of a new disease awareness campaign titled “We’ll Get There Soon” on FCS Awareness Day. The initiative aims to raise awareness about Familial Chylomicronemia Syndrome (FCS), a rare and severe condition…